International Clinical Trial: Efficacy and Safety of Tuvonralimab/Iparomlimab Combined with Paclitaxel in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Progressed on Prior First-Line Standard Therapy: A Prospective, Single-Arm, Single-Center Clinical Trial

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600128548) titled 'Efficacy and Safety of Tuvonralimab/Iparomlimab Combined with Paclitaxel in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Progressed on Prior First-Line Standard Therapy: A Prospective, Single-Arm, Single-Center Clinical Trial' on July 22.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Foshan Nanhai District People's Hospital

Condition: Advanced gastric or gastroesophageal junction adenocarcinoma

Recruitment Status: Not Recruiting

Phase: 4

Date of First Enrollment: 2026-08-01

Target Sample Size: Study Arm:15;

Countries of Recruitment:...